Hims & Hers rises after plan to sell Eli Lilly's weight loss drug on its platform

LifeMD

01/04/2025 19:23

** Shares of telehealth firm Hims & Hers HIMS.N rise 11.2% to $32.88

** HIMS says it plans  to sell Eli Lilly's LLY.N weight-loss and diabetes drug on its platform

** Co says it will offer both branded versions of Lilly's tirzepatide, the active ingredient in weight loss drug Zepbound and diabetes medicine Mounjaro, as well as generics of Novo Nordisk's NOVOb.CO diabetes drug, liraglutide

     ** HIMS joins its peers such as Teladoc TDOC.N and LifeMD LFMD.O to offer Lilly's Zepbound ahead of restrictions on selling copies known as compounded drugs

** Including session's moves, HIMS stock up 36.4% YTD

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))